Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Aclarion, Inc. Common Stock

ACON

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.37 – $1.43
Volume 6,529
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.01M
Price / earnings
—
Price / book
0.27×
Price / sales
40.65×
EV / sales
-103.3×
EV / EBITDA
0.98×

Profitability

Earnings per share
-$3.51
Return on assets
-63.86%
Return on equity
-68.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
14.17×
Quick ratio
14.17×
Cash ratio
13.79×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ACON, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$33.73K$25.21K$21.14K$18.48K$18.94K$19.32K$18.99K$10.23K
Cost of revenue$18.94K$16.91K$17.39K$16.69K$14.56K$14.18K$23.48K$20.56K
Gross profit$14.8K$8.3K$3.75K$1.79K$4.39K$5.14K-$4.49K-$10.32K
Selling, general and administrative$2.4M$2.61M$2.68M$1.73M$1.53M$1.47M$1.29M$1.54M
Research and development$371.51K$297.07K$315.42K$263.13K$302.04K$270.43K$198.19K$251.83K
Total operating expenses$2.77M$2.91M$2.99M$1.99M$1.84M$1.74M$1.49M$1.8M
Operating income-$2.75M-$2.9M-$2.99M-$1.99M-$1.83M-$1.74M-$1.49M-$1.81M
Interest expense$0$0$0$0$0$0$0-$271
Income before taxes-$2.62M-$2.75M-$2.85M-$1.89M-$1.71M-$1.6M-$2.04M-$1.99M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.62M-$2.75M-$2.85M-$1.89M-$1.71M-$1.6M-$2.04M-$1.99M
Net income attributable to common shareholders-$2.62M-$2.75M-$2.85M-$1.89M-$1.71M-$1.6M-$2.04M-$2.04M
EBITDA-$2.69M-$2.84M-$2.93M-$1.93M-$1.77M-$1.68M-$1.44M-$1.75M
Basic earnings per share-$0.94-$1.12-$1.34-$2.54-$2.93-$2.75-$9.32—
Diluted earnings per share-$0.94-$1.12-$1.34-$2.54-$2.93-$2.75-$9.32—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Ardent Health, Inc. (ARDT) Beats Q3 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.24, with revenues of $1.62 billion slightly exceeding expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends. The stock has outperformed the S&P 500 by 22% year-to-date, but future performance will depend on management guidance and earnings estimate revisions.

GlobeNewswire Inc.

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion reported 85% year-over-year scan volume growth in Q3 2026 and 117% growth for the nine-month period. The company expanded its CLARITY clinical trial to eleven sites with updated enrollment criteria and published peer-reviewed data in the European Spine Journal supporting its Nociscan technology as an alternative to provocative discography. With $14.2 million in cash, Aclarion has runway into the second half of 2027 to fully fund the 300-patient trial.

GlobeNewswire Inc.

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.

GlobeNewswire Inc.

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform and generate real-world evidence. The partnership will evaluate how Nociscan's chemical biomarker measurements work alongside SPECT-CT imaging to improve diagnostic precision for chronic low back pain treatment decisions.

GlobeNewswire Inc.

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Aclarion's Nociscan MRS technology was used in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The research found that elevated propionic acid levels in lumbar discs can identify a subgroup of Modic type 1 patients with distinct immune activation, suggesting potential applications beyond surgical decision support for personalized spine care and immune-modulating therapies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 28, 20251-for-27reverse split
Jan 30, 20251-for-335reverse split
Jan 4, 20241-for-16reverse split